Market Cap 3.06B
Revenue (ttm) 2.79B
Net Income (ttm) -116.89M
EPS (ttm) N/A
PE Ratio 14.36
Forward PE 13.88
Profit Margin -4.18%
Debt to Equity Ratio -21.93
Volume 1,604,600
Avg Vol 1,525,634
Day's Range N/A - N/A
Shares Out 314.08M
Stochastic %K 99%
Beta 1.19
Analysts Strong Sell
Price Target $12.00

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and r...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 947 3120
Fax: 908 947 3146
Address:
400 Crossing Boulevard, 3rd Floor, Bridgewater, United States
BigSqueezeComing
BigSqueezeComing Sep. 8 at 7:52 PM
$AMRX Going to 10
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 8 at 7:52 PM
$AMRX loading up.
0 · Reply
sandford1
sandford1 Sep. 5 at 1:37 PM
$AMRX What is this fda warning letter for this company. Anyone know?
1 · Reply
G101SPM
G101SPM Sep. 5 at 9:53 AM
$AMRX $9.35 bid. DAC $8.20 (8.20.24). EXIT EXIT TO $16.00 from $12.00. BRIEF: Amneal Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen's Risperdal Consta®. The product is eligible for 180-day exclusivity under the FDA's Competitive Generic Therapy (CGT) designation. note: Product launch is planned for the fourth quarter of 2025
0 · Reply
Lefthandedchef
Lefthandedchef Sep. 5 at 3:23 AM
$AMRX watching for tomorrow
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 4 at 8:09 PM
$AMRX hot ah movers
0 · Reply
bSpeed
bSpeed Sep. 4 at 8:06 PM
$AMRX Amneal Pharmaceuticals Inc. Gains FDA Approval for Innovative Multichambered Bag Presentation of TEPADINA® 200 mg for Enhanced Oncology Treatment
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 4 at 8:03 PM
$AMRX FDA approval headline here Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
0 · Reply
Quantumup
Quantumup Sep. 4 at 2:34 PM
Roth • MKM🏁 $SPRY at a Buy rating and a $40 price target. $AQST $VTRS $TEVA $AMRX ORXOY Roth • MKM said: We are initiating coverage of $SPRY with a Buy rating and $40 PT. Approved in March, neffy® is the first needle-free way to administer epinephrine, representing a vast improvement over auto-injectors in terms of safety, dosing, and form factor. With already 93% commercial payer coverage and a DTC campaign underway, we expect an aggressive ramp leading to at least 60% share of the epinephrine market with a $3 billion market opportunity and upside from market expansion.
1 · Reply
scientificway
scientificway Sep. 3 at 4:05 PM
$AMRX strong buy. PMN, strong support. Should be 0.5-1 no brainer for so cheap
0 · Reply
Latest News on AMRX
Amneal Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 6:00 AM EDT - 5 weeks ago

Amneal Reports Second Quarter 2025 Financial Results


Amneal to Report Second Quarter 2025 Results on August 5, 2025

Jul 9, 2025, 8:00 AM EDT - 2 months ago

Amneal to Report Second Quarter 2025 Results on August 5, 2025


Amneal to Participate at Upcoming Investor Conferences in June

May 29, 2025, 4:05 PM EDT - 3 months ago

Amneal to Participate at Upcoming Investor Conferences in June


US FDA approves Amneal's migraine treatment

May 15, 2025, 8:16 AM EDT - 4 months ago

US FDA approves Amneal's migraine treatment


Amneal Reports First Quarter 2025 Financial Results

May 2, 2025, 6:00 AM EDT - 4 months ago

Amneal Reports First Quarter 2025 Financial Results


Amneal to Report First Quarter 2025 Results on May 2, 2025

Apr 8, 2025, 4:05 PM EDT - 5 months ago

Amneal to Report First Quarter 2025 Results on May 2, 2025


Amneal to Participate at Upcoming Investor Conference

Mar 10, 2025, 4:05 PM EDT - 6 months ago

Amneal to Participate at Upcoming Investor Conference


Amneal to Participate at Upcoming Investor Conferences

Dec 4, 2024, 8:00 AM EST - 10 months ago

Amneal to Participate at Upcoming Investor Conferences


Amneal Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 6:00 AM EST - 10 months ago

Amneal Reports Third Quarter 2024 Financial Results


Melina Kennedy Joins the LDI, Ltd. Board of Managers

Aug 20, 2024, 9:45 AM EDT - 1 year ago

Melina Kennedy Joins the LDI, Ltd. Board of Managers

WBTN


Amneal Reports Second Quarter 2024 Financial Results

Aug 9, 2024, 6:05 AM EDT - 1 year ago

Amneal Reports Second Quarter 2024 Financial Results


Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10, 2024, 11:40 AM EDT - 1 year ago

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success


BigSqueezeComing
BigSqueezeComing Sep. 8 at 7:52 PM
$AMRX Going to 10
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 8 at 7:52 PM
$AMRX loading up.
0 · Reply
sandford1
sandford1 Sep. 5 at 1:37 PM
$AMRX What is this fda warning letter for this company. Anyone know?
1 · Reply
G101SPM
G101SPM Sep. 5 at 9:53 AM
$AMRX $9.35 bid. DAC $8.20 (8.20.24). EXIT EXIT TO $16.00 from $12.00. BRIEF: Amneal Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen's Risperdal Consta®. The product is eligible for 180-day exclusivity under the FDA's Competitive Generic Therapy (CGT) designation. note: Product launch is planned for the fourth quarter of 2025
0 · Reply
Lefthandedchef
Lefthandedchef Sep. 5 at 3:23 AM
$AMRX watching for tomorrow
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 4 at 8:09 PM
$AMRX hot ah movers
0 · Reply
bSpeed
bSpeed Sep. 4 at 8:06 PM
$AMRX Amneal Pharmaceuticals Inc. Gains FDA Approval for Innovative Multichambered Bag Presentation of TEPADINA® 200 mg for Enhanced Oncology Treatment
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 4 at 8:03 PM
$AMRX FDA approval headline here Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
0 · Reply
Quantumup
Quantumup Sep. 4 at 2:34 PM
Roth • MKM🏁 $SPRY at a Buy rating and a $40 price target. $AQST $VTRS $TEVA $AMRX ORXOY Roth • MKM said: We are initiating coverage of $SPRY with a Buy rating and $40 PT. Approved in March, neffy® is the first needle-free way to administer epinephrine, representing a vast improvement over auto-injectors in terms of safety, dosing, and form factor. With already 93% commercial payer coverage and a DTC campaign underway, we expect an aggressive ramp leading to at least 60% share of the epinephrine market with a $3 billion market opportunity and upside from market expansion.
1 · Reply
scientificway
scientificway Sep. 3 at 4:05 PM
$AMRX strong buy. PMN, strong support. Should be 0.5-1 no brainer for so cheap
0 · Reply
tamperson
tamperson Sep. 1 at 2:42 AM
$AMRX As of the end of August 2025, the consensus among 14 analysts is that AMRX is a Buy, with some platforms characterizing it as a Moderate Buy and others as a Strong Buy. Price targets are generally in the $11.50–$12.00 range, implying a potential ~20–22% upside from the current price of around $9.56. A very good company, with an excellent drug pipeline, growing revenues, a buy-out candidate that will drive a premium price. Almost nothing not to like with this company. GLTA!
0 · Reply
scientificway
scientificway Aug. 27 at 5:47 PM
$AMRX strong buy, XTNT revenue up year over year. check it out, anyone there?
0 · Reply
OptionWitcher
OptionWitcher Aug. 23 at 5:33 AM
$AMRX Amneal Pharmaceuticals is a generic drug maker facing industry pricing pressure and regulatory challenges
0 · Reply
tamperson
tamperson Aug. 22 at 12:43 AM
$AMRX Insider Sell-Offs Recently: Over the last 3 months, corporate insiders have sold approximately $1.8 million worth of AMRX shares, with no reported insider purchases during that period. Specifically, in mid-August 2025: Tasos Konidaris (Executive VP & CFO) sold a total of 499,730 shares across three days: 161,365 shares on August 13 at ~$9.22 119,206 shares on August 14 at ~$9.30 19,159 shares on August 15 at ~$9.43 After these transactions, he hold 122,152 shares. Nikita Shah (Executive VP) sold 71,694 shares on August 14, at an average price of $9.29 per share; she retained 267,235 shares afterward. Additional notable sellers include: Andrew Boyer (EVP) sold shares valued at $1,111,250 in a November 2024 transaction. Other insiders, such as Jason Daly and Deborah Autor, recorded smaller sales between November 2024 and early 2025. I like the stock too. Also finding other company Exec's selling much of their Performance Earned stock - to the point it is frustrating- suggests no confidence.
0 · Reply
STKip86bny
STKip86bny Aug. 21 at 2:13 PM
$AMRX another day, another insider sell. There haven't been any insider purchases since 2021 with officers selling majority of the shares in possession Daly (95%), Boyer (95%), Tasos (83%), and Nikita (45%). I like the stock, but will follow this insiders lead and reduce exposure by 50%.
0 · Reply
STKip86bny
STKip86bny Aug. 20 at 3:19 PM
$AMRX Quite a lot of insider selling with no purchase interest by company insiders. Not a good look as historically this indicates a falling stock.
0 · Reply
scientificway
scientificway Aug. 15 at 5:26 AM
$AMRX Loaded, XTNT, check it out, anyone there?
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Aug. 12 at 1:57 PM
$AMRX Is a monster in the making. Buy all dips
0 · Reply
scientificway
scientificway Aug. 5 at 4:21 AM
$AMRX check out MDXG, huge rev, eps, guidance up. , Chance to get in before explode
0 · Reply
tamperson
tamperson Aug. 4 at 7:40 PM
$AMRX Analyst sentiment on AMRX is overwhelmingly positive, with consensus ratings ranging from “Buy” to “Strong Buy”. Public.com reports a blend of Strong Buy (29%), Buy (29%), Hold (36%), and a small Strong Sell portion (7%), based on coverage from 14 analysts. MarketBeat and StockAnalysis list AMRX as a Strong Buy with a consensus target of $11.50 (~+46.5% upside). GLTA!
0 · Reply
tamperson
tamperson Jul. 24 at 9:29 PM
$AMRX Recent News & Analyst Views: • Q2 2025 Earnings Date Confirmed: Amneal is scheduled to report earnings on August 5, 2025, before market open. • Analyst Consensus: MarketBeat shows a “Buy” consensus with an average price target of $11.60, implying ~45% upside. • Bullish Momentum Story: SimplyWall.St models AMRX as 31% undervalued, forecasting 93% annual earnings growth and signaling strong future potential. Current Range: Trading near $8.00, down ~0.9% intraday, with volume (~765K) below its 50 day average (~1.9M). Volume Context: Light volume in recent days suggests a quiet consolidation phase heading into earnings, lacking strong buying or selling pressure.
0 · Reply
tamperson
tamperson Jul. 21 at 5:04 PM
$AMRX Recent News Highlights 1. Proposed $2.55 B Debt Refinancing: Amneal's subsidiary (Amneal Pharmaceuticals), has launched a major debt restructuring plan. It’s seeking $1.8 billion in seven-year term B loans and issuing $750 million in senior secured notes due 2032. Funds will refinance existing loans, reduce asset-based borrowings, and cover related expenses. This refinancing aims to optimize Amneal’s debt profile, especially by extending maturities and possibly securing better interest terms. 2. Solid Q2 2025 Preliminary Results: Amneal released unaudited preliminary Q2 results through June 30, 2025: Revenue:$720–730 million (+3% YoY) Adjusted EBITD$180–185 million (+13% YoY) Gross leverage reduced from 4.1× to 3.8×; net leverage from 3.9× to 3.7× Pre-tax income rose to $45–56 million vs. $20 million last year. Pipeline wins:FDA approvedBrekiya autoinjector for migraine and cluster headache;strong commercial uptake of CREXONT®; planningBLA submission for Xolair biosimilar in Q4 25.
0 · Reply